![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis Pays DOJ $729 Million To Settle Kickback Allegations
Novartis Pays DOJ $729 Million To Settle Kickback Allegations
July 6, 2020
Novartis has agreed to pay $729 million to settle kickback allegations made by the Department of Justice.
The Swiss drugmaker will pay $678 million to settle allegations that it hosted sham speaker programs and other events to bribe doctors into prescribing its medicines.
The company will also pay $51.25 million to settle allegations that it used charitable foundations to pay patient copays for its multiple sclerosis drug Gilenya (fingolimod) and its cancer drug Afinitor (everolimus).
Upcoming Events
-
21Oct